<SEC-DOCUMENT>0001817160-26-000010.txt : 20260625
<SEC-HEADER>0001817160-26-000010.hdr.sgml : 20260625
<ACCEPTANCE-DATETIME>20260625184910
ACCESSION NUMBER:		0001817160-26-000010
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260625
FILED AS OF DATE:		20260625
DATE AS OF CHANGE:		20260625

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Hansen Gwenn
		CENTRAL INDEX KEY:			0001817160
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39398
		FILM NUMBER:		261123450

	MAIL ADDRESS:	
		STREET 1:		C/O NURIX THERAPEUTICS, INC.
		STREET 2:		1700 OWENS STREET, SUITE 205
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nurix Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001549595
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				270838048
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	BUSINESS ADDRESS:	
		STREET 1:		1600 SIERRA POINT PKWY
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(415) 660-5320

	MAIL ADDRESS:	
		STREET 1:		1600 SIERRA POINT PKWY
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nurix, Inc.
		DATE OF NAME CHANGE:	20120509
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1782427748.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0609</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-06-25</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001549595</issuerCik>
        <issuerName>Nurix Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>NRIX</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001817160</rptOwnerCik>
            <rptOwnerName>Hansen Gwenn</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>C/O NURIX THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1600 SIERRA POINT PKWY</rptOwnerStreet2>
            <rptOwnerCity>BRISBANE</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94005</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Scientific Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2026-06-25</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5394</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>20</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>115005</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen</signatureName>
        <signatureDate>2026-06-25</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
